Ascentage Pharma Group International (AAPG) Non-Current Assets (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Non-Current Assets for 3 consecutive years, with $143.7 million the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Assets fell 9.73% year-over-year to $143.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $143.7 million (down 9.73% YoY) and the FY2025 annual result came in at $145.8 million, down 6.96% from the prior year.
• Non-Current Assets retreated to $143.7 million in Q4 2025 per AAPG's latest filing, from $158.8 million in the prior quarter.
• Over the last five years, Non-Current Assets for AAPG reached as high as $160.6 million in Q4 2023 and fell as low as $143.7 million in Q4 2025.
• A 3-year average of $155.6 million and a median of $159.0 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets decreased 0.85% — and 2025, when it declined 9.73%.
• Year by year, Non-Current Assets stood at $160.6 million in 2023, then fell by 0.85% to $159.2 million in 2024, then fell by 9.73% to $143.7 million in 2025.
• According to Business Quant data, Non-Current Assets over the past three periods registered $143.7 million, $158.8 million, and $159.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.